{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T11:49:43Z","timestamp":1792064983117,"version":"4.4.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"vor","delay-in-days":92,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-62237-4","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T11:37:39Z","timestamp":1784115459000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tegoprazan-based dual therapy versus bismuth-containing quadruple therapy for Helicobacter pylori eradication: a prospective, multicenter, open-label, non-inferiority, randomized controlled trial"],"prefix":"10.1038","volume":"16","author":[{"given":"Haocheng","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunming","family":"Fei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meijuan","family":"Xi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minyi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxin","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhimei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"issue":"8390","key":"62237_CR1","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1016\/s0140-6736(84)91816-6","volume":"1","author":"BJ Marshall","year":"1984","unstructured":"Marshall, B. J. & Warren, J. R. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1(8390), 1311\u20131315. https:\/\/doi.org\/10.1016\/s0140-6736(84)91816-6 (1984).","journal-title":"Lancet"},{"issue":"12","key":"62237_CR2","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1056\/NEJMcp1710945","volume":"380","author":"SE Crowe","year":"2019","unstructured":"Crowe, S. E. Helicobacter pylori infection. N. Engl. J. Med. 380(12), 1158\u20131165. https:\/\/doi.org\/10.1056\/NEJMcp1710945 (2019).","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"62237_CR3","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/S2468-1253(23)00070-5","volume":"8","author":"Y Li","year":"1980","unstructured":"Li, Y. et al. Global prevalence of Helicobacter pylori infection between 1980 and 2022: A systematic review and meta-analysis. Lancet Gastroenterol. Hepatol. 8(6), 553\u2013564. https:\/\/doi.org\/10.1016\/S2468-1253(23)00070-5 (1980).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"62237_CR4","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2022-327745","author":"P Malfertheiner","year":"2022","unstructured":"Malfertheiner, P. et al. Management of Helicobacter pylori infection: The Maastricht VI\/Florence consensus report. Gut https:\/\/doi.org\/10.1136\/gutjnl-2022-327745 (2022).","journal-title":"Gut"},{"issue":"24","key":"62237_CR5","doi-asserted-by":"publisher","first-page":"2899","DOI":"10.1097\/CM9.0000000000002546","volume":"135","author":"L Zhou","year":"2022","unstructured":"Zhou, L. et al. 2022 Chinese national clinical practice guideline on Helicobacter pylori eradication treatment. Chin. Med. J. (Engl.) 135(24), 2899\u20132910. https:\/\/doi.org\/10.1097\/CM9.0000000000002546 (2022).","journal-title":"Chin. Med. J. (Engl.)"},{"issue":"4","key":"62237_CR6","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12692","volume":"25","author":"CP Gao","year":"2020","unstructured":"Gao, C. P. et al. Ppi-amoxicillin dual therapy for Helicobacter pylori infection: An update based on a systematic review and meta-analysis. Helicobacter 25(4), e12692. https:\/\/doi.org\/10.1111\/hel.12692 (2020).","journal-title":"Helicobacter"},{"issue":"1","key":"62237_CR7","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/CM9.0000000000002565","volume":"136","author":"M Duan","year":"2023","unstructured":"Duan, M., Liu, J. & Zuo, X. Dual therapy for Helicobacter pylori infection. Chin. Med. J. 136(1), 13\u201323. https:\/\/doi.org\/10.1097\/CM9.0000000000002565 (2023).","journal-title":"Chin. Med. J."},{"issue":"1","key":"62237_CR8","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S2468-1253(23)00281-9","volume":"9","author":"TC Hong","year":"1990","unstructured":"Hong, T. C. et al. Primary antibiotic resistance of Helicobacter pylori in the Asia-Pacific region between 1990 and 2022: An updated systematic review and meta-analysis. Lancet Gastroenterol. Hepatol. 9(1), 56\u201367. https:\/\/doi.org\/10.1016\/S2468-1253(23)00281-9 (1990).","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"4","key":"62237_CR9","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12970","volume":"28","author":"J Hu","year":"2023","unstructured":"Hu, J. et al. Eradication rates of Helicobacter pylori in treatment-naive patients following 14-day vonoprazan-amoxicillin dual therapy: A multicenter randomized controlled trial in China. Helicobacter 28(4), e12970. https:\/\/doi.org\/10.1111\/hel.12970 (2023).","journal-title":"Helicobacter"},{"key":"62237_CR10","doi-asserted-by":"publisher","first-page":"1128574252","DOI":"10.1177\/17562848251391276","volume":"18","author":"J YANG","year":"2025","unstructured":"YANG, J. & ZHANG, X. Comparison of tegoprazan-based high-dose dual therapy versus bismuth-containing quadruple therapy for helicobacter pylori eradication: a prospective, multicentre, randomised controlled trial in gansu province, a high-resistance region of china[J]. Ther. Adv. Gastroenterol. 18, 1128574252. https:\/\/doi.org\/10.1177\/17562848251391276 (2025).","journal-title":"Ther. Adv. Gastroenterol."},{"key":"62237_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2023.1294379","volume":"13","author":"W Wei","year":"2018","unstructured":"Wei, W. et al. Antibiotic resistance of Helicobacter pylori in Nanjing, China: A cross-section study from 2018 to 2023. Front. Cell. Infect. Microbiol. 13, 1294379. https:\/\/doi.org\/10.3389\/fcimb.2023.1294379 (2018).","journal-title":"Front. Cell. Infect. Microbiol."},{"issue":"1","key":"62237_CR12","doi-asserted-by":"publisher","DOI":"10.1111\/hel.13040","volume":"29","author":"BG Zhou","year":"2024","unstructured":"Zhou, B. G. et al. Vonoprazan-amoxicillin dual therapy versus bismuth-containing quadruple therapy for Helicobacter pylori eradication: A systematic review and meta-analysis. Helicobacter 29(1), e13040. https:\/\/doi.org\/10.1111\/hel.13040 (2024).","journal-title":"Helicobacter"},{"issue":"3","key":"62237_CR13","doi-asserted-by":"publisher","DOI":"10.1111\/hel.13098","volume":"29","author":"Q Kong","year":"2024","unstructured":"Kong, Q. et al. Fourteen-day tegoprazan-amoxicillin dual therapy as the first-line treatment of Helicobacter pylori infection (share2301): A multicenter, noninferiority, randomized clinical trial. Helicobacter 29(3), e13098. https:\/\/doi.org\/10.1111\/hel.13098 (2024).","journal-title":"Helicobacter"},{"issue":"10","key":"62237_CR14","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.14309\/ctg.0000000000000699","volume":"15","author":"HN Liu","year":"2024","unstructured":"Liu, H. N. et al. Comparison of the efficacy between the dual therapy of tegoprazan and the quadruple therapy of tegoprazan: A randomized controlled multicenter study. Clin. Transl. Gastroenterol. 15(10), e1. https:\/\/doi.org\/10.14309\/ctg.0000000000000699 (2024).","journal-title":"Clin. Transl. Gastroenterol."},{"issue":"4","key":"62237_CR15","doi-asserted-by":"publisher","first-page":"524","DOI":"10.14309\/ajg.0000000000001659","volume":"117","author":"DY Graham","year":"2022","unstructured":"Graham, D. Y. & Moss, S. F. Antimicrobial susceptibility testing for Helicobacter pylori is now widely available: When, how, why. Am. J. Gastroenterol. 117(4), 524\u2013528. https:\/\/doi.org\/10.14309\/ajg.0000000000001659 (2022).","journal-title":"Am. J. Gastroenterol."},{"issue":"9","key":"62237_CR16","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/s41575-021-00449-x","volume":"18","author":"E Tshibangu-Kabamba","year":"2021","unstructured":"Tshibangu-Kabamba, E. & Yamaoka, Y. Helicobacter pylori infection and antibiotic resistance - from biology to clinical implications. Nat. Rev. Gastroenterol. Hepatol. 18(9), 613\u2013629. https:\/\/doi.org\/10.1038\/s41575-021-00449-x (2021).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"5","key":"62237_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2024.107325","volume":"64","author":"S Zeng","year":"2024","unstructured":"Zeng, S. et al. Antibiotic resistance of Helicobacter pylori in mainland China: A focus on geographic differences through systematic review and meta-analysis. Int. J. Antimicrob. Agents 64(5), 107325. https:\/\/doi.org\/10.1016\/j.ijantimicag.2024.107325 (2024).","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"1","key":"62237_CR18","doi-asserted-by":"publisher","DOI":"10.1111\/hel.13039","volume":"29","author":"RC Du","year":"2024","unstructured":"Du, R. C. et al. Vonoprazan and amoxicillin dual therapy as the first-line treatment of Helicobacter pylori infection: A systematic review and meta-analysis. Helicobacter 29(1), e13039. https:\/\/doi.org\/10.1111\/hel.13039 (2024).","journal-title":"Helicobacter"},{"issue":"2","key":"62237_CR19","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1053\/j.gastro.2023.09.047","volume":"166","author":"SF Moss","year":"2024","unstructured":"Moss, S. F. et al. Evolving concepts in Helicobacter pylori management. Gastroenterology 166(2), 267\u2013283. https:\/\/doi.org\/10.1053\/j.gastro.2023.09.047 (2024).","journal-title":"Gastroenterology"},{"issue":"6","key":"62237_CR20","doi-asserted-by":"publisher","DOI":"10.1111\/hel.13151","volume":"29","author":"X Lin","year":"2024","unstructured":"Lin, X. et al. Tegoprazan-amoxicillin dual therapy for Helicobacter pylori eradication: A prospective, randomized, multicenter study in Fujian, China. Helicobacter 29(6), e13151. https:\/\/doi.org\/10.1111\/hel.13151 (2024).","journal-title":"Helicobacter"},{"issue":"7","key":"62237_CR21","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1111\/apt.15438","volume":"50","author":"S Han","year":"2019","unstructured":"Han, S. et al. Randomised clinical trial: Safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple oral doses of tegoprazan (CJ-12420), a novel potassium-competitive acid blocker, in healthy male subjects. Aliment. Pharmacol. Ther. 50(7), 751\u2013759. https:\/\/doi.org\/10.1111\/apt.15438 (2019).","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"32","key":"62237_CR22","doi-asserted-by":"publisher","first-page":"11415","DOI":"10.3748\/wjg.v20.i32.11415","volume":"20","author":"Y Xie","year":"2014","unstructured":"Xie, Y. et al. Furazolidone-based triple and quadruple eradication therapy for Helicobacter pylori infection. World J. Gastroenterol. 20(32), 11415\u201311421. https:\/\/doi.org\/10.3748\/wjg.v20.i32.11415 (2014).","journal-title":"World J. Gastroenterol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-62237-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-62237-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-62237-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T10:59:36Z","timestamp":1792061976000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-62237-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["62237"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-62237-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"assertion":[{"value":"9 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Medical Ethics Committee of Nanjing First Hospital Affiliated to Nanjing Medical University (Approval No.: KY20240123-05) prior to initiation. The trial is registered with ClinicalTrials.gov (Website: https:\/\/register.clinicaltrials.gov\/, Registration ID: NCT06340334). The study was conducted in accordance with the Declaration of Helsinki. All participants were fully informed of potential risks and provided written informed consent.","order":2,"name":"Ethics","label":"<b>Ethics<\/b>","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"32413"}}